ClinicalTrials.Veeva

Menu
A

American Oncology Network | Zangmeister Cancer Center

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Sacituzumab
Platinum
Leucovorin
Avutometinib
Pembrolizumab
Oxaliplatin
Disitamab
Pertuzumab
Folate
Atezolizumab

Parent organization

This site is a part of American Oncology Network

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 20 total trials

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)

The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in part...

Enrolling
Gastrointestinal Tract Malignancies
Drug: Quemliclustat
Drug: Zimberelimab
Locations recently updated

PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following p...

Enrolling
Small Cell Lung Cancer
Drug: Alisertib

This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal ca...

Active, not recruiting
Metastatic Colorectal Cancer
Colon Cancer
Drug: CTX-009

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your b...

Enrolling
HER2 Positive Breast Neoplasms
HER2 Low Breast Neoplasms
Drug: tucatinib
Drug: disitamab vedotin

This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine (MIRV) vs. IC chemotherapy in participants with platin...

Active, not recruiting
Epithelial Ovarian Cancer
Peritoneal Cancer
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin

The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's...

Enrolling
Neoplasms, Ovarian
Drug: Topotecan
Drug: Paclitaxel

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast ca...

Active, not recruiting
HER2 Positive Breast Cancer
Drug: Pertuzumab
Drug: Trastuzumab

The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: RMC-4630
Drug: Sotorasib

This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in...

Active, not recruiting
Non-Small Cell Lung Carcinoma
Nonsmall Cell Lung Cancer
Drug: efineptakin alfa
Drug: Atezolizumab

A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR...

Active, not recruiting
Non-Squamous Non-small Cell Lung Cancer
Drug: Placebo Injection
Drug: AK112 Injection

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 m...

Enrolling
Salivary Gland Cancer
Adenoid Cystic Carcinoma
Drug: ONC-392
Drug: Docetaxel

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinom...

Enrolling
Endometrial Cancer
Drug: Matching Placebo for selinexor
Drug: Selinexor

The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or meta...

Active, not recruiting
Non-Small Cell Lung Cancer
Biological: Sacituzumab Govitecan-hziy (SG)
Drug: Docetaxel

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versu...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase...

Active, not recruiting
Cancer
Drug: cetuximab
Drug: TTX-080

Trial sponsors

Gilead Sciences logo
Bristol-Myers Squibb (BMS) logo
Seagen logo
Arcus Biosciences logo
C
C
ImmunoGen logo
Karyopharm Therapeutics logo
M
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems